Investigation of Secreted Phosphoproteins and PiP3 (Phosphoinositolphospat 3) in Sputum
Study Details
Study Description
Brief Summary
The aim of this study is to validate two new biomarkers in sputum samples. These are PiP3 (phosphoinositolphospat ) and phosphor proteins, representing important proteins within inflammatory situations of the lung.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Within the study, sputum samples will be collected at 3 repetitive occasions in a 3 week interval of the different donors.
The objective is to assess for biomarker specificity and reproducibility in the two groups (smokers and non-smokers). The methods for measurement shall be validated by repetitive measurement of the sputum samples, i.e. comparison of multiple measurements of the same sample and comparison of different samples from the same donor.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: induced sputum procedure Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors. |
Other: Induced sputum procedure
induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
|
Outcome Measures
Primary Outcome Measures
- Biomarker assessment [up to 3 weeks]
concentration of PiP3 and phosphoproteins in sputum samples
Eligibility Criteria
Criteria
Inclusion Criteria:
- • Healthy male and female subjects, aged 25-45 years. Women will be considered for inclusion if they are not pregnant, as confirmed by pregnancy test and not nursing.
Females of childbearing potential need to use a highly effective method of contraception during the entire study (vasectomised partner, sexual abstinence - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the first visit until at least 72 hours after the last visit -, implants, injectables, combined oral contraceptives, hormonal IUDs (intrauterine device) or double-barrier methods, i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap).
-
Body weight ≥ 50 kg and BMI (body mass index) within the range 19-32 kg/m²
-
Smokers need to consume at least ten cigarettes per day and need to have at least ten packyear
-
Non-smokers need to be non-smoking since at least a year with a smoking history of no more than 1 packyear.
-
FEV1 (forced expiratory volume at one second)≥80% predicted and FEV1/FVC (forced expiratory vital capacity) ≥70%
Exclusion Criteria:
-
• History of an acute infection four weeks prior to the informed consent visit.
-
Regular intake of medication.
-
Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
-
Participation in another clinical trial 30 days prior to enrollment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fraunhofer ITEM | Hannover | Niedersachsen | Germany | 30625 |
Sponsors and Collaborators
- Fraunhofer-Institute of Toxicology and Experimental Medicine
Investigators
- Principal Investigator: Jens Hohlfeld, MD, Fraunhofer-Institute of Toxicology and Experimental Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 16-11 SPUFO I